Tradestie Institutional Equity Comparison Engine

NIO vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NIO Overall Edge

NIO Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to NIO Inc. American depositary shares, each representing one Class A ordinary share (NIO) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, NIO trades at 48.5x Forward P/E with -3.3% operating margin (+69.1% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, NIO sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
NIO 48.5x vs MRNA 23.0x Fwd P/E
Growth & Margin Winner NIO
Op Margin -3.3% vs -80.8% ยท YoY +69.1% vs +29.2%
Momentum & Technical Winner MRNA
1Y -57.4% vs +706.5% ยท 52W Pos 0% vs 67%
Options & Structure Winner NIO
BREAKDOWN (50th %ile IV) vs CONSOLIDATION (52nd %ile IV)
NIO NYSE
NIO Inc. American depositary shares, each representing one Class A ordinary share
Motor Vehicles & Passenger Car Bodies
$2.45
-7.89% 1D
Market Cap $6.3B
1M Return -25.98%
1Y Return -57.39%
Forward P/E 48.5x
Unified AI Score
43.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 71.0 Mom 55.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NIO -57.39% MRNA +706.45% Spread: +763.84 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NIO Revenue MRNA Revenue NIO Op. Margin MRNA Op. Margin Margin Edge
FY2018 $720M $140M -193.8% -306.0% NIO
FY2019 $1.12B $60M -141.6% -906.8% NIO
FY2020 $2.49B $800M -28.3% -95.0% NIO
FY2021 $5.67B $18.5B -12.4% 72.0% MRNA
FY2022 $7.14B $19.3B -31.7% 48.9% MRNA
FY2023 $7.83B $6.85B -40.7% -61.9% NIO
FY2024 $9.01B $3.24B -33.3% -121.9% NIO
FY2025 $12.5B $1.94B -16.0% -158.1% NIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NIO (5) vs MRNA (5)
Institutional Metric NIO MRNA Criterion Row Winner
Market Capitalization Scale $6.3B $80.7B Larger Scale MRNA
Trailing P/E Ratio Valuation 48.5x 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation 48.5x 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth +69.1% +29.2% Higher Growth NIO
Operating Margin (TTM) Profitability -3.3% -80.8% Higher Margin NIO
Net Profit Margin Profitability -4.2% -110.5% Higher Margin NIO
Return on Equity (ROE) Capital Efficiency -45.3% -34.5% Higher ROE MRNA
52-Week Range Position Momentum 0% ($2โ€“$7) 67% ($22โ€“$281) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 1.31ฮฒ ยท 53% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk NIO
Unified Institutional Score Composite Signal 43.9 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite NIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NIO vs MRNA Buy Guide
NIO BREAKDOWN
152d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NIO nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.